CPMG Inc
CIK 1372218 · last filed 2024-05-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$406.19M
Companies
4
Total Filings
32
Lifetime Open-Market Net
$99.43M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRCT | 10%+ Owner | 2,828,204 | $17.79 | $50.31M | $33.00M | 4 | 2024-05-07 |
| Apollo Endosurgery, Inc. (APEN) Delisted | 10%+ Owner | 0 | $10.00 | $0 | $7.53M | 4 | 2023-04-04 |
| REATA PHARMACEUTICALS INC (RETA) Delisted | Director | 5,577 | $172.36 | $961.3K | $47.62M | 18 | 2020-12-29 |
| GTOP | 10%+ Owner | 7,889,947 | $45.10 | $355.88M | $11.28M | 4 | 2007-06-13 |
Recent Filings · Page 2 of 4
32 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-11-18 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +40,218 | $7.36M | EDGAR |
| 2018-12-12 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +110,826 | $6.58M | EDGAR |
| 2017-12-29 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +17,000 | $484.0K | EDGAR |
| 2017-12-28 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +27,200 | $705.4K | EDGAR |
| 2017-12-28 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +34,897 | $864.9K | EDGAR |
| 2017-12-15 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +200,000 | $4.96M | EDGAR |
| 2017-06-23 | REATA PHARMACEUTICALS INC (RETA) Delisted | Mixed | +742,289 | $0 | EDGAR |
| 2017-01-04 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +9,392 | $204.0K | EDGAR |
| 2016-12-20 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +164,753 | $3.79M | EDGAR |
| 2016-12-16 | REATA PHARMACEUTICALS INC (RETA) Delisted | Buy (P) | +8,889 | $191.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.